Hypoxia-Inducible Factor in Thyroid Carcinoma

被引:39
作者
Burrows, Natalie [1 ]
Babur, Muhammad [1 ]
Resch, Julia [2 ]
Williams, Kaye J. [1 ]
Brabant, Georg [2 ]
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Hypoxia & Therapeut Grp, Oxford Rd, Manchester M13 9PT, Lancs, England
[2] Med Klin I, Expt & Clin Endocrinol, D-23538 Lubeck, Germany
基金
英国惠康基金;
关键词
D O I
10.4061/2011/762905
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intratumoural hypoxia (low oxygen tension) is associated with aggressive disease and poor prognosis. Hypoxia-inducible factor-1 is a transcription factor activated by hypoxia that regulates the expression of genes that promote tumour cell survival, progression, metastasis, and resistance to chemo/radiotherapy. In addition to hypoxia, HIF-1 can be activated by growth factor-signalling pathways such as the mitogen-activated protein kinases-(MAPK-) and phosphatidylinositol-3-OH kinases-(PI3K-) signalling cascades. Mutations in these pathways are common in thyroid carcinoma and lead to enhanced HIF-1 expression and activity. Here, we summarise current data that highlights the potential role of both hypoxia and MAPK/PI3K-induced HIF-1 signalling in thyroid carcinoma progression, metastatic characteristics, and the potential role of HIF-1 in thyroid carcinoma response to radiotherapy. Direct or indirect targeting of HIF-1 using an MAPK or PI3K inhibitor in combination with radiotherapy may be a new potential therapeutic target to improve the therapeutic response of thyroid carcinoma to radiotherapy and reduce metastatic burden.
引用
收藏
页数:17
相关论文
共 129 条
  • [1] Reasons to reconsider the significance of apoptosis for cancer therapy
    Abend, M
    [J]. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2003, 79 (12) : 927 - 941
  • [2] Aebersold DM, 2001, CANCER RES, V61, P2911
  • [3] ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER
    ALLRED, DC
    CLARK, GM
    ELLEDGE, R
    FUQUA, SAW
    BROWN, RW
    CHAMNESS, GC
    OSBORNE, CK
    MCGUIRE, WL
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) : 200 - 206
  • [4] Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection
    Aprelikova, Olga
    Wood, Matthew
    Tackett, Sean
    Chandramouli, Gadisetti V. R.
    Barrett, J. Carl
    [J]. CANCER RESEARCH, 2006, 66 (11) : 5641 - 5647
  • [5] Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer
    Astanehe, Arezoo
    Arenillas, David
    Wasserman, Wyeth W.
    Leung, Peter C. K.
    Dunn, Sandra E.
    Davies, Barry R.
    Mills, Gordon B.
    Auersperg, Nelly
    [J]. JOURNAL OF CELL SCIENCE, 2008, 121 (05) : 664 - 674
  • [6] VHL and HIF signalling in renal cell carcinogenesis
    Baldewijns, Marcella M.
    van Vlodrop, Iris J. H.
    Vermeulen, Peter B.
    Soetekouw, Patricia M. M. B.
    van Engeland, Manon
    de Bruine, Adriaan P.
    [J]. JOURNAL OF PATHOLOGY, 2010, 221 (02) : 125 - 138
  • [7] Hypoxia-inducible factor-1 and oncogenic signalling
    Bárdos, JI
    Athcroft, M
    [J]. BIOESSAYS, 2004, 26 (03) : 262 - 269
  • [8] Biomarkers as Predictors of Response to Treatment with Motesanib in Patients with Progressive Advanced Thyroid Cancer
    Bass, Michael B.
    Sherman, Steven I.
    Schlumberger, Martn J.
    Davis, Michael T.
    Kivman, Lisa
    Khoo, Huan-Mei
    Notari, Kimberly H.
    Peach, Matthew
    Hei, Yong-jiang
    Patterson, Scott D.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (11) : 5018 - 5027
  • [9] PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR
    Bernardi, Rosa
    Guernah, Ilhem
    Jin, David
    Grisendi, Silvia
    Alimonti, Andrea
    Teruya-Feldstein, Julie
    Cordon-Cardo, Carlos
    Simon, M. Celeste
    Rafii, Shahin
    Pandolfi, Pier Paolo
    [J]. NATURE, 2006, 442 (7104) : 779 - 785
  • [10] Signaling angiogenesis via p42/p44 MAP kinase and hypoxia
    Berra, E
    Milanini, J
    Richard, DE
    Le Gall, M
    Viñals, F
    Gothié, E
    Roux, D
    Pagès, G
    Pouysségur, J
    [J]. BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) : 1171 - 1178